Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Rising Leverage • Persistent Losses NUVB has ample liquidity but worsening leverage, persistent cash burn, and weak profitability make its high valuation difficult to justify.
Price Behavior
Key Price Behavior Insights: • Persistent downtrend • Support holding • Rebound rejected Support Level: $5.78 Resistance Level: $6.07 NUVB remains bearish last month, with $5.78 support critical and a reclaim of $6.07 needed to improve momentum.
Sentiment & News
Key News Insights: • Early FDA Approval • Fast Track Progress • Speculative Valuation Nuvation Bio's accelerated IBTROZI approval and safusidenib Fast Track status strengthen its growth outlook, though the stock remains a high-risk speculative play.
AI Summary
NUVB is now an execution-driven commercial oncology story: IBTROZI's differentiated ROS1 data and early share gains create meaningful upside, but investors should wait for revenue growth to outpace its roughly $43M quarterly cash burn and validate sustainable margins before underwriting pipeline value.
Description
Nuvation Bio is a clinical-stage biopharmaceutical company developing small-molecule therapies for oncology, with its lead candidate NUV-422 targeting CDK2, CDK4 and CDK6. Its pipeline also includes oral inhibitors affecting BET proteins, Wee1 kinase, and adenosine receptors, along with a drug–drug conjugate platform that pairs PARP inhibition with cytotoxic warheads to treat cancers including ER+ breast and ovarian tumors. The company was founded in 2018, rebranded from RePharmation in 2019, and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 5 | Jan 12 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop. | Closed | -24.8% |
| Sep 15 | Sep 22 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s near-term FDA approval and early commercial launch of IBTROZI™, strong cash runway, and positive technical signals with a 13.8% gain over three weeks establish it as a hot idea, balanced with caution on volatility and rising leverage risks before more commercial data emerge. | Closed | +3.8% |